SNNA Insider Trading Activity and SEC Form 4 Filings
SNNA insider trading summary
No open-market insider purchases or sales of Sienna Biopharmaceuticals, Inc. (SNNA) have been reported on SEC Form 4 in the past 12 months.
Latest SNNA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 22, 2019 | ARCH Venture Partners X Overage, L.P. | 10% Owner | Buy | $375K (150,000 @ $2.50) |
| Feb 22, 2019 | Keith Crandell | 10% Owner | Buy | $375K (150,000 @ $2.50) |
| Feb 22, 2019 | ARCH Venture Partners VIII, L.P. | 10% Owner | Buy | $375K (150,000 @ $2.50) |
| Feb 22, 2019 | Keith Crandell | 10% Owner | Buy | $4.7M (1,865,800 @ $2.50) |
| Feb 22, 2019 | Steven Gillis | 10% Owner | Buy | $4.7M (1,865,800 @ $2.50) |
| Feb 22, 2019 | Clinton Bybee | 10% Owner | Buy | $4.7M (1,865,800 @ $2.50) |
| Feb 22, 2019 | Keith Crandell | 10% Owner | Buy | $4.7M (1,865,800 @ $2.50) |
| Feb 22, 2019 | Steven Gillis | 10% Owner | Buy | $375K (150,000 @ $2.50) |
| Feb 22, 2019 | ARCH Venture Fund VIII, L.P. | 10% Owner | Buy | $375K (150,000 @ $2.50) |
| Feb 22, 2019 | Robert J More | Insider | Buy | $250K (100,000 @ $2.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.